Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07515924 · ClinicalTrials.gov registry record · Early Phase 1
Oral Gallium Maltolate for Recurrent Glioblastoma
A Early Phase 1 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT07515924 is a Early Phase 1 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 8 participants.
The verdict
NCT07515924, a Early Phase 1 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 0 investigational study to assess the central nervous system penetration and tumoral concentration of gallium in patients with recurrent glioblastoma administered with preoperative gallium maltolate.
Interventions
- PROCEDURE Surgical Intervention
- DRUG Gallium Maltolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07515924
The ClinicalTrials.gov registry entry for NCT07515924 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgical Intervention is the first listed.
NCT07515924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07515924 about?
NCT07515924 is a clinical study titled "Oral Gallium Maltolate for Recurrent Glioblastoma". This is a Phase 0 investigational study to assess the central nervous system penetration and tumoral concentration of gallium in patients with recurrent glioblastoma administered with preoperative gallium maltolate.
What is the current status of trial NCT07515924?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2026-06. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07515924?
The interventions under investigation include: Surgical Intervention (PROCEDURE), Gallium Maltolate (DRUG).
Who is sponsoring clinical trial NCT07515924?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.